50 trials changed in the last 30 days: 1 stopped, 18 with notable changes, 31 with minor changes only.
Trial terminated
Sponsor's reason: The interim analysis data failed to demonstrate the intended treatment effect.
Eli Lilly and CompanyPhase 2 NCT06220669 Registry history of NCT06220669 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jan 2028 to Oct 2028
Also in this update: Enrollment reduced: 127 → 90 participants
Eli Lilly and CompanyPhase 1 NCT06809400 Registry history of NCT06809400 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Apr 2027 to Sep 2028
Eli Lilly and CompanyPhase 1 NCT07226843 Registry history of NCT07226843 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Phase changed: Phase 1/2 → Phase 3; Sponsor changed: Akouos, Inc. to Eli Lilly and Company
Eli Lilly and CompanyPhase 3 NCT05821959 Registry history of NCT05821959 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 3 NCT07817875 Registry history of NCT07817875 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07801300 Registry history of NCT07801300 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07808060 Registry history of NCT07808060 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07808073 Registry history of NCT07808073 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 1 NCT07787169 Registry history of NCT07787169 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 3 NCT07775300 Registry history of NCT07775300 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Start date changed from estimate of Sep 2026 to Aug 26, 2026
Eli Lilly and CompanyPhase 3 NCT07794579 Registry history of NCT07794579 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 2 NCT07759245 Registry history of NCT07759245 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 2 NCT07783802 Registry history of NCT07783802 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07803744 Registry history of NCT07803744 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07818967 Registry history of NCT07818967 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07765498 Registry history of NCT07765498 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07794592 Registry history of NCT07794592 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07767487 Registry history of NCT07767487 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
And 2 more changes in the last 30 days
Eli Lilly and CompanyNot specified NCT07254234 Registry history of NCT07254234 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Phase 2 NCT05611671 Registry history of NCT05611671 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Eli Lilly and CompanyPhase 4 NCT07006792 Registry history of NCT07006792 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Eli Lilly and CompanyPhase 1 NCT07662798 Registry history of NCT07662798 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Primary completion date changed from estimate of Dec 2026 to Apr 2, 2025
Eli Lilly and CompanyPhase 1 NCT05307705 Registry history of NCT05307705 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 2 NCT07215559 Registry history of NCT07215559 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
And 2 more changes in the last 30 days
Eli Lilly and CompanyPhase 2 NCT06598943 Registry history of NCT06598943 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 1 NCT07707375 Registry history of NCT07707375 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jul 2030 to Sep 2030
Also in this update: Trial sites expanded: 9 → 12 locations; Start date pushed from Oct 2026 to Nov 2026
Eli Lilly and CompanyPhase 4 NCT07838155 Registry history of NCT07838155 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 3 NCT07153471 Registry history of NCT07153471 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Eli Lilly and CompanyPhase 1 NCT06280703 Registry history of NCT06280703 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Eli Lilly and CompanyPhase 1 NCT07545590 Registry history of NCT07545590 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Eli Lilly and CompanyPhase 2 NCT06603571 Registry history of NCT06603571 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Primary and study completion moved earlier from Nov 2027 to Aug 2027
Eli Lilly and CompanyPhase 4 NCT06864026 Registry history of NCT06864026 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 1 NCT07701083 Registry history of NCT07701083 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Eli Lilly and CompanyPhase 1 NCT07346495 Registry history of NCT07346495 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Final enrollment: 200 participants (planned 225)
Eli Lilly and CompanyPhase 1 NCT06148272 Registry history of NCT06148272 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 1 NCT07021547 Registry history of NCT07021547 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jul 2026 to Nov 2026
Eli Lilly and CompanyPhase 1 NCT06606106 Registry history of NCT06606106 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Aug 2026 to Nov 2026
Eli Lilly and CompanyPhase 1 NCT07165002 Registry history of NCT07165002 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 2026 to Mar 2027
Eli Lilly and CompanyPhase 1 NCT06945406 Registry history of NCT06945406 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 0 → 18 locations
Eli Lilly and CompanyPhase 2 NCT07814417 Registry history of NCT07814417 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 136 → 131 locations
Eli Lilly and CompanyPhase 3 NCT07222332 Registry history of NCT07222332 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 148 → 143 locations
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 3 NCT07282600 Registry history of NCT07282600 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 284 → 276 locations
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 3 NCT07218380 Registry history of NCT07218380 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 3 → 10 locations
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 4 NCT07822880 Registry history of NCT07822880 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 161 → 170 locations
Eli Lilly and CompanyPhase 3 NCT07223593 Registry history of NCT07223593 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 162 → 158 locations
Eli Lilly and CompanyPhase 3 NCT07321886 Registry history of NCT07321886 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 11 → 15 locations
Eli Lilly and CompanyPhase 1 NCT07598370 Registry history of NCT07598370 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 10 → 16 locations
Eli Lilly and CompanyPhase 1 NCT07787182 Registry history of NCT07787182 on ClinicalTrials.gov (opens the registry)
Updated
Study completion moved earlier from May 2029 to Feb 2029
Also in this update: Primary completion moved earlier from May 2028 to Feb 2028
Eli Lilly and CompanyPhase 1/2 NCT06721013 Registry history of NCT06721013 on ClinicalTrials.gov (opens the registry)
Updated
Interventions modified
Also in this update: Trial arms changed: 12 → 15
Eli Lilly and CompanyPhase 2 NCT05986292 Registry history of NCT05986292 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-09 | NCT07867327 A Study of LY4515100 in Healthy Male Participants | Phase 1 | Not Yet Recruiting |
| 2026-10-09 | NCT07867340 A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including… | Phase 1 | Not Yet Recruiting |
| 2026-09-28 | NCT07843459 A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease… | Phase 1 | Not Yet Recruiting |
| 2026-09-24 | NCT07838155 A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's… | Phase 4 | Not Yet Recruiting |
| 2026-09-18 | NCT07827612 A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and… | Phase 2 | Not Yet Recruiting |
| 2026-09-16 | NCT07822880 A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection… | Phase 4 | Not Yet Recruiting |
| Phase 1 | 69 | |
| Phase 1/2 | 5 | |
| Phase 2 | 43 | |
| Phase 2/3 | 1 | |
| Phase 3 | 92 | |
| Phase 4 | 11 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic… | Chronic Lymphocytic Leukemia | Recruiting | 2026-09-22 |
| NCT07247084 | A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants… | Obesity | Recruiting | 2026-09-09 |
| NCT07612267 | A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving… | Lactation | Recruiting | 2026-09-08 |
| NCT06857942 | A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation… | Psoriasis | Recruiting | 2026-09-04 |
| NCT06876649 | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | Chronic Lymphocytic Leukemia | Recruiting | 2026-03-02 |
| NCT06876662 | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic… | Chronic Lymphocytic Leukemia | Recruiting | 2026-03-02 |
| NCT07838155 | A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's… | Alzheimer Disease | Not Yet Recruiting | 2026-10-15 |
| NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection… | Thyroid Neoplasms | Not Yet Recruiting | 2026-10-08 |
| NCT06864026 | A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in… | Psoriatic Arthritis | Active, Not Recruiting | 2026-09-21 |
| NCT07438444 | A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2… | Diabetes Mellitus, Type 2 | Active, Not Recruiting | 2026-08-21 |
| NCT05433584 | A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants… | Type 2 Diabetes | Active, Not Recruiting | 2025-12-12 |
| Phase 3 | ||||
| NCT07817875 | Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus… | Obesity | Recruiting | 2026-10-13 |
| NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated… | Metabolic Dysfunction-Associated Steatotic Liver Disease | Recruiting | 2026-10-08 |
| NCT07174336 | A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in… | Breast Neoplasms | Recruiting | 2026-10-08 |
| NCT07202884 | A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have… | Urinary Incontinence,Stress | Recruiting | 2026-10-08 |
| NCT07213804 | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With… | Ovarian Neoplasms | Recruiting | 2026-10-08 |
| NCT07219953 | A Study of Brenipatide in Participants With Alcohol Use Disorder | Alcohol Use Disorder | Recruiting | 2026-10-08 |
| NCT07222137 | A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk… | Diabetes Mellitus, Type 1 | Recruiting | 2026-10-08 |
| NCT07222332 | A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults… | Diabetes Mellitus, Type 1 | Recruiting | 2026-10-08 |
| NCT07223593 | Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease | Peripheral Arterial Disease | Recruiting | 2026-10-08 |
| NCT07241390 | A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With… | Atherosclerosis Cardiovascular Disease | Recruiting | 2026-10-08 |
| NCT07282600 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type… | Overweight | Recruiting | 2026-10-08 |
| NCT07353931 | Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee… | Osteoarthritis | Recruiting | 2026-10-08 |
| NCT07369011 | A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and… | Sleep Apnea, Obstructive | Recruiting | 2026-10-08 |
| NCT07613294 | A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With… | Atherosclerosis | Recruiting | 2026-10-08 |
Obesity (50) · Breast Cancer (25) · Diabetes (25) · Alzheimer's Disease (19) · Dementia (19) · Lung Cancer (19) · Non-Small Cell Lung Cancer (NSCLC) (19) · Type 2 Diabetes (18) · Colorectal Cancer (10) · Head & Neck Cancer (8)